Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of denosumab on osteoporotic vertebral fracture healing
ChiCTR2200062124Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab in vertebral compression fracture (VCF) and fragility fracture (2 arms), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoints: Bone mineral density and Radiographic vertebral height (X-ray). Planned start Aug 2022; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
vertebral compression fracture (VCF)fragility fracture
Beyond the preview
Go deeper on ChiCTR2200062124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062124.